PL411864A1 - Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy P13 - Google Patents

Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy P13

Info

Publication number
PL411864A1
PL411864A1 PL411864A PL41186415A PL411864A1 PL 411864 A1 PL411864 A1 PL 411864A1 PL 411864 A PL411864 A PL 411864A PL 41186415 A PL41186415 A PL 41186415A PL 411864 A1 PL411864 A1 PL 411864A1
Authority
PL
Poland
Prior art keywords
compound
pyrazolo
morpholin
pyrimidine
kinase
Prior art date
Application number
PL411864A
Other languages
English (en)
Other versions
PL236355B1 (pl
Inventor
Barbara Dymek
Marcin Zagozda
Maciej Wieczorek
Krzysztof Dubiel
Aleksandra Stańczak
Daria Zdżalik
Paweł Gunerka
Mariola Sekular
Maciej Dziachan
Original Assignee
Celon Pharma Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma Spółka Akcyjna filed Critical Celon Pharma Spółka Akcyjna
Priority to PL411864A priority Critical patent/PL236355B1/pl
Priority to CN201680017259.4A priority patent/CN107743489B/zh
Priority to CA2978828A priority patent/CA2978828A1/en
Priority to AU2016241568A priority patent/AU2016241568B2/en
Priority to PCT/IB2016/051792 priority patent/WO2016157091A1/en
Priority to PT167140193T priority patent/PT3277687T/pt
Priority to EA201792087A priority patent/EA032826B1/ru
Priority to ES16714019T priority patent/ES2765642T3/es
Priority to US15/562,537 priority patent/US10138247B2/en
Priority to MX2017011423A priority patent/MX2017011423A/es
Priority to HUE16714019A priority patent/HUE047822T2/hu
Priority to SI201630560T priority patent/SI3277687T1/sl
Priority to DK16714019.3T priority patent/DK3277687T3/da
Priority to BR112017020131-3A priority patent/BR112017020131B1/pt
Priority to KR1020177031214A priority patent/KR102559190B1/ko
Priority to PL16714019T priority patent/PL3277687T3/pl
Priority to EP16714019.3A priority patent/EP3277687B1/en
Priority to HRP20192195TT priority patent/HRP20192195T1/hr
Priority to JP2017551627A priority patent/JP6665201B2/ja
Publication of PL411864A1 publication Critical patent/PL411864A1/pl
Publication of PL236355B1 publication Critical patent/PL236355B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Ujawniono związek o wzorze ogólnym (I), w którym Y oznacza -CH2- lub >C=O; R1 oznacza grupę wybraną z grup A1, A2 i A3 zdefiniowanych w opisie; R2 oznacza grupę wybraną z grup B1, B2, B3 i B4 zdefiniowanych w opisie; R3 oznacza H, halogen, lub C1-C4 alkil; R4 oznacza C1-C4 alkil, C3-C4-cykloalkil, C1-C4 alkil podstawiony przez C1-C4 alkoksyl, lub CHF2; jego dopuszczalne farmaceutycznie sole, oraz kompozycja farmaceutyczna zawierająca związek o wzorze (I). Związek jest selektywnym inhibitorem izoformy delta kinazy PI3 i znajduje zastosowanie jako lek w leczeniu chorób układu immunologicznego, chorób o podłożu zapalnym i nowotworów.
PL411864A 2015-04-02 2015-04-02 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3 PL236355B1 (pl)

Priority Applications (19)

Application Number Priority Date Filing Date Title
PL411864A PL236355B1 (pl) 2015-04-02 2015-04-02 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
CN201680017259.4A CN107743489B (zh) 2015-04-02 2016-03-30 治疗免疫疾病、炎性疾病或癌症的7-(吗啉-4-基)吡唑并[1，5-a]嘧啶衍生物
CA2978828A CA2978828A1 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer
AU2016241568A AU2016241568B2 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer
PCT/IB2016/051792 WO2016157091A1 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer
PT167140193T PT3277687T (pt) 2015-04-02 2016-03-30 Derivados de 7-(morfolin-4-il)pirazole[1,5-a]pirimidina que são úteis para o tratamento de doenças imunitárias ou inflamatórias ou cancro
EA201792087A EA032826B1 (ru) 2015-04-02 2016-03-30 ПРОИЗВОДНЫЕ 7-(МОРФОЛИН-4-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИМИДИНА, ПРИГОДНЫЕ ДЛЯ ЛЕЧЕНИЯ ИММУННЫХ ИЛИ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ИЛИ РАКА
ES16714019T ES2765642T3 (es) 2015-04-02 2016-03-30 Derivados de 7-(morfolin-4-il)pirazol[1,5-a]pirimidina que son útiles para el tratamiento de enfermedades inmunitarias o inflamatorias o cáncer
US15/562,537 US10138247B2 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-A]pyrimidine derivatives as PI3 kinase inhibitors
MX2017011423A MX2017011423A (es) 2015-04-02 2016-03-30 Derivados de 7-(morfolin-4-il)pirazolo[1,5-a]pirimidina que son utiles para el tratamiento de enfermedades inmunes o inflamatorias o cancer.
HUE16714019A HUE047822T2 (hu) 2015-04-02 2016-03-30 Immun- vagy gyulladásos betegségek és rák kezelésére alkalmas 7-(morfolin-4-il)pirazol[1,5-a]pirimidin-származékok
SI201630560T SI3277687T1 (sl) 2015-04-02 2016-03-30 7-(morfolin-4-IL)pirazol(1,5-A)pirimidinski derivati, ki so uporabni za zdravljenje imunskih ali vnetnih bolezni ali raka
DK16714019.3T DK3277687T3 (da) 2015-04-02 2016-03-30 7-(Morpholin-4-yl)pyrazol[1,5-a]pyrimidinderivater, som kan anvendes til behandling af immunsygdomme eller inflammatoriske sygdomme eller cancer
BR112017020131-3A BR112017020131B1 (pt) 2015-04-02 2016-03-30 Composto, seu uso e composição farmacêutica
KR1020177031214A KR102559190B1 (ko) 2015-04-02 2016-03-30 면역성 또는 염증성 질환 또는 암의 치료를 위해 유용한 7-(모르폴린-4-일)피라졸[1,5-a]피리미딘 유도체
PL16714019T PL3277687T3 (pl) 2015-04-02 2016-03-30 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-a]pirymidyny użyteczne do leczenia chorób immunologicznych lub zapalnych lub nowotworów
EP16714019.3A EP3277687B1 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer
HRP20192195TT HRP20192195T1 (hr) 2015-04-02 2016-03-30 Derivati 7-(morfolin-4-il)pirazol[1,5-a]pirimidina koji su korisni za liječenje imunoloških ili upalnih oboljenja ili karcinoma
JP2017551627A JP6665201B2 (ja) 2015-04-02 2016-03-30 免疫もしくは炎症性の疾患またはがんの処置に有用な７−（モルホリン−４−イル）ピラゾール［１，５−ａ］ピリミジン誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL411864A PL236355B1 (pl) 2015-04-02 2015-04-02 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3

Publications (2)

Publication Number Publication Date
PL411864A1 true PL411864A1 (pl) 2016-10-10
PL236355B1 PL236355B1 (pl) 2021-01-11

Family

ID=55650626

Family Applications (2)

Application Number Title Priority Date Filing Date
PL411864A PL236355B1 (pl) 2015-04-02 2015-04-02 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
PL16714019T PL3277687T3 (pl) 2015-04-02 2016-03-30 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-a]pirymidyny użyteczne do leczenia chorób immunologicznych lub zapalnych lub nowotworów

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16714019T PL3277687T3 (pl) 2015-04-02 2016-03-30 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-a]pirymidyny użyteczne do leczenia chorób immunologicznych lub zapalnych lub nowotworów

Country Status (18)

Country Link
US (1) US10138247B2 (pl)
EP (1) EP3277687B1 (pl)
JP (1) JP6665201B2 (pl)
KR (1) KR102559190B1 (pl)
CN (1) CN107743489B (pl)
AU (1) AU2016241568B2 (pl)
BR (1) BR112017020131B1 (pl)
CA (1) CA2978828A1 (pl)
DK (1) DK3277687T3 (pl)
EA (1) EA032826B1 (pl)
ES (1) ES2765642T3 (pl)
HR (1) HRP20192195T1 (pl)
HU (1) HUE047822T2 (pl)
MX (1) MX2017011423A (pl)
PL (2) PL236355B1 (pl)
PT (1) PT3277687T (pl)
SI (1) SI3277687T1 (pl)
WO (1) WO2016157091A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12486274B2 (en) 2020-01-13 2025-12-02 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
WO2022064458A1 (en) * 2020-09-28 2022-03-31 1ST Biotherapeutics, Inc. Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
EP4229063A4 (en) * 2020-10-19 2024-12-25 TME Therapeutics LLC NOVEL PIKFYVE INHIBITORS AND METHODS OF USE THEREOF
CN114957261B (zh) * 2022-05-17 2023-06-23 重庆文理学院 一种具有抗头颈癌作用的化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2168237T3 (es) * 1996-02-07 2007-04-01 Neurocrine Biosciences, Inc. Pirazolopirimidinas como antagonistas de receptores de crf.
CN1918172B (zh) 2003-12-23 2011-09-14 活跃生物工艺学公司 利福霉素类似物及其用途
ATE512966T1 (de) * 2005-02-11 2011-07-15 Hoffmann La Roche Pyrazolo-pyrimidin-derivate als mglur2- antagonisten
KR101088239B1 (ko) * 2006-09-20 2011-11-30 일라이 릴리 앤드 캄파니 Ｃｒｆ１ 수용체 길항제로서의 티아졸 피라졸로피리미딘
JP5638955B2 (ja) * 2007-10-26 2014-12-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｐｉ３キナーゼ阻害剤として有用なプリン誘導体
EA201001359A1 (ru) 2008-02-26 2011-04-29 Новартис Аг Гетероциклические соединения в качестве ингибиторов cxcr2
ES2533788T3 (es) * 2008-05-30 2015-04-14 Genentech, Inc. Compuestos inhibidores de PI3K de tipo purina y métodos de uso
WO2010037765A2 (en) * 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
WO2010074284A1 (ja) * 2008-12-26 2010-07-01 味の素株式会社 ピラゾロピリミジン化合物
NZ596185A (en) * 2009-04-16 2013-01-25 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
SG182247A1 (en) 2009-05-27 2012-08-30 Hoffmann La Roche Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
MX2011012520A (es) * 2009-05-27 2011-12-12 Hoffmann La Roche Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos.
GB0912745D0 (en) 2009-07-22 2009-08-26 Wolfson Microelectronics Plc Improvements relating to DC-DC converters
MX2012009059A (es) 2010-02-22 2012-09-07 Hoffmann La Roche Compuestos inhibidores de fosfoinositida 3-cinasa delta (pi3k) pirido [3,2-d]pirimidina y metodos de uso.
CA2789475C (en) 2010-03-04 2018-05-29 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
WO2013028263A1 (en) * 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors

Also Published As

Publication number Publication date
ES2765642T3 (es) 2020-06-10
BR112017020131B1 (pt) 2023-02-28
CN107743489A (zh) 2018-02-27
HUE047822T2 (hu) 2020-05-28
KR102559190B1 (ko) 2023-07-25
HRP20192195T1 (hr) 2020-03-06
AU2016241568B2 (en) 2019-09-26
SI3277687T1 (sl) 2020-02-28
US20180111939A1 (en) 2018-04-26
PL3277687T3 (pl) 2020-09-21
US10138247B2 (en) 2018-11-27
EA032826B1 (ru) 2019-07-31
JP6665201B2 (ja) 2020-03-13
BR112017020131A2 (pt) 2018-05-29
PL236355B1 (pl) 2021-01-11
EP3277687A1 (en) 2018-02-07
DK3277687T3 (da) 2019-12-16
PT3277687T (pt) 2020-01-10
CN107743489B (zh) 2021-05-04
KR20170132275A (ko) 2017-12-01
AU2016241568A1 (en) 2017-10-19
JP2018510192A (ja) 2018-04-12
CA2978828A1 (en) 2016-10-06
MX2017011423A (es) 2018-05-17
EP3277687B1 (en) 2019-10-30
EA201792087A1 (ru) 2018-03-30
WO2016157091A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
CR20220062A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo [3,4-b]pirazina
MX2019015431A (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
NZ766835A (en) Pharmaceutical compounds
EA201992082A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
EA202090291A3 (ru) Производные бипиразола в качестве ингибиторов jak
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
DK3873884T3 (da) 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
BR112018004175A2 (pt) novo composto pirazolo[3,4-d]pirimidina ou sal deste
PL415078A1 (pl) Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
EA201650029A1 (ru) Пиразолопиридины и пиразолопиримидины
EA201792116A1 (ru) Ингибитор янус-киназы
EA201000947A1 (ru) Производные тиазола, применимые в качестве ингибиторов киназы pi3
WO2014106800A8 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
NZ598144A (en) Kinase inhibitors, prodrug forms thereof and their use in therapy
BR112015024971A2 (pt) derivados de n-(2,3-di-hidro-1h-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina e n-(2,3-di-hidro-1h-indol-5-il)-4-quinazolinamina como inibidores de perk
MX2019008331A (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
GEP20186934B (en) Quinolizinone derivatives as pi3k inhibitors
MX2022004878A (es) Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.
PL407081A1 (pl) Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK-2
MX2017011423A (es) Derivados de 7-(morfolin-4-il)pirazolo[1,5-a]pirimidina que son utiles para el tratamiento de enfermedades inmunes o inflamatorias o cancer.
PH12020500366A1 (en) The salts of a compound and the crystalline forms thereof
BR112018007720A2 (pt) novos derivados de piridona e seu uso como inibidores da quinase